Oblique Therapeutics, will present the recent progress on its anti-Thioredoxin mAb program at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, Nov 10 -14, Washington DC, USA.
The poster titled ” Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-Thioredoxin antibody ” will describe the identification of high affinity monoclonal antibodies against human Thioredoxin and in vitro and in vivo characterization of these antibodies.
Plasma levels of Trx1 is elevated in patients with lung, breast, colorectal, pancreatic, hepatocellular, gastric, myeloma, non-Hodgkin lymphoma and acute lymphatic lymphocytic leukemia. Trx1 is believed to be a survival factor and chemoattractant to Tregs in tumor microenvironment (TME) resulting in inhibition of cytotoxic T cells and NK cells. By neutralizing Trx1 in TME, an aTRX mAb is hypothesized to reduce Treg and other suppressive cells and activate T effector cells, thereby resulting in anti-tumor immune response and reduction in formation of pre-metastatic niche.
